Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Retrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in COPD Patients Initiating Trixeo Aerosphere (Budesonide/Glycopyrronium Bromide/Formoterol Fumarate) in Spain

NCT06321731 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06321731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06321731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Retrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in COPD Patients Initiating Trixeo Aerosphere (Budesonide/Glycopyrronium Bromide/Formoterol Fumarate) in Spain
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
July 2, 2024
Completion date
December 16, 2024
Enrollment
718 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)